Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT: 12-week dosing interval of benralizumab in stable severe asthma
jRCTs031240259Phase 2Recruiting
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benralizumab in asthma and severe asthma. Primary endpoint: Annual asthma exacerbation rate. Started Nov 2024; status: recruiting.
02
Drugs
benralizumab
03
Conditions
asthmasevere asthma
Beyond the preview
Go deeper on jRCTs031240259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240259.